Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Proliferative Diabetic Retinopathy: early-phase trial registry
1 of 5 indexed Non-Proliferative Diabetic Retinopathy trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Non-Proliferative Diabetic Retinopathy: 5 US clinical trials tracked, 1 recruiting.
Non-Proliferative Diabetic Retinopathy is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Allegro Ophthalmics, running 1 of these trials.
Enrollment posture brief
Registry condition non-proliferative-diabetic-retinopathy
OPEN 1 | RECR 20% | LATE 1 | EARLY 3 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Non-Proliferative Diabetic Retinopathy lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Proliferative Diabetic Retinopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Proliferative Diabetic Retinopathy is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Non-Proliferative Diabetic Retinopathy research.
Allegro Ophthalmics accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Proliferative Diabetic Retinopathy enrolment sits around 114 participants.
Median target enrolment is 114 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.
-
Non-Proliferative Diabetic Retinopathy research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
Ocular Therapeutix
NCT07235085
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
Valo Health
NCT05393284
Safety and Efficacy of Faricimab in Patients With NPDR
Greater Houston Retina Research
NCT05681884
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
Allegro Ophthalmics
NCT02435862
Diabetes Visual Function Supplement Study
ZeaVision
NCT01646047
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Proliferative Diabetic Retinopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Proliferative Diabetic Retinopathy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Proliferative Diabetic Retinopathy page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Non-Proliferative Diabetic Retinopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Allegro Ophthalmics sponsors the most Non-Proliferative Diabetic Retinopathy trials on record, review their full trial history before evaluating a specific study. See Allegro Ophthalmics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Proliferative Diabetic Retinopathy condition card totals 5 registered trials; most-linked intervention Balanced Salt Solution for intravitreal injection in 0.10cc; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.